Individualized Treatment Strategy for Depressive Disorder

被引:3
|
作者
Chen, Jun [1 ,2 ]
Hu, Shaohua [3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Clin Res Ctr, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Div Mood Disorders, Shanghai Mental Hlth Ctr, Shanghai, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Psychiat, Hangzhou, Peoples R China
关键词
Depressive disorders; Individualized treatment; Precision medicine; Genomics; Neural circuit; Artificial intelligence; MEASUREMENT-BASED CARE; NEUROTROPHIC FACTOR; PRECISION MEDICINE; MAJOR DEPRESSION; 2ND-GENERATION ANTIDEPRESSANTS; SEROTONIN TRANSPORTER; ANXIETY TREATMENTS; CANADIAN NETWORK; CONTROLLED-TRIAL; BRAIN;
D O I
10.1007/978-981-32-9271-0_12
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The goal of treatment for depressive disorders is complete remission of depressive symptoms with full recovery of social function and prevention of recurrence. However, a large proportion of patients do not experience symptomatic remission after the initial treatment, with even lower rates of remission in the longer treatment term. The main objective of individualized treatment applied in psychiatry is to improve precision in disease diagnosis, prognosis, treatment choices, and treatment response. Diverse approaches and techniques, such as genomics, epigenomics, other omics, neural circuit, and artificial intelligence are related to precision psychiatry. Using biology and computational psychiatry tools to find potential biomarkers, and based on precision psychiatry, patients considered to belong to the same endophenotype will be possible to receive biomarkers-based treatment and better prognosis. Especially in the choice of intervention, individualized treatment should be considered. In this review, we present the development of precise treatment in depressive disorders and introduce advances in several domains toward precision medicine and individualized treatment. We pay particular attention to biomarkers and the development of new technologies in depressive disorders, which will help disease complete remission and functional recovery, seek better lives for patients suffered with depressive disorders.
引用
收藏
页码:219 / 232
页数:14
相关论文
共 50 条
  • [21] Lithium in the Treatment of Major Depressive Disorder
    Bschor, Tom
    DRUGS, 2014, 74 (08) : 855 - 862
  • [22] Treatment guidelines for major depressive disorder
    Hollon, SD
    Shelton, RC
    BEHAVIOR THERAPY, 2001, 32 (02) : 235 - 258
  • [23] Amantadine: a treatment for major depressive disorder
    Ruiz-Chow, A.
    Ramirez-Bermudez, J.
    Alviso-de la Serna, L.
    Rios, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S352 - S352
  • [24] Vortioxetine for the treatment of major depressive disorder
    Tritschler, Laurent
    Felice, Daniela
    Colle, Romain
    Guilloux, Jean-Philippe
    Corruble, Emmanuelle
    Gardier, Alain Michel
    David, Denis Joseph
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (06) : 731 - 745
  • [25] Agomelatine Treatment of Major Depressive Disorder
    Dolder, Christian R.
    Nelson, Michael
    Snider, Morgan
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (12) : 1822 - 1831
  • [26] Vortioxetine in the treatment of major depressive disorder
    Baldwin, David S.
    Hanumanthaiah, Venkatesh Ballagere
    FUTURE NEUROLOGY, 2015, 10 (02) : 79 - 89
  • [27] Diagnosis and Treatment of Major Depressive Disorder
    Soleimani, Laili
    Lapidus, Kyle A. B.
    Iosifescu, Dan V.
    NEUROLOGIC CLINICS, 2011, 29 (01) : 177 - +
  • [28] Vilazodone for the Treatment of Major Depressive Disorder
    Iranikhah, Maryam
    Wensel, Terri M.
    Thomason, Angela R.
    PHARMACOTHERAPY, 2012, 32 (10): : 958 - 965
  • [29] Desvenlafaxine in the treatment of major depressive disorder
    Lourenco, Maria Teresa C.
    Kennedy, Sidney H.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2009, 5 : 127 - 136
  • [30] Desvenlafaxine for the treatment of major depressive disorder
    Kornstein, Susan G.
    McIntyre, Roger S.
    Thase, Michael E.
    Boucher, Matthieu
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1449 - 1463